Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: A preliminary study using in vivo proton magnetic resonance spectroscopy (<sup>1</sup>H MRS)

Giles M Y Tan*, Felix Beacher, Eileen Daly, Jamie Horder, Verinder Prasher, Maria Luisa Hanney, Robin Morris, Simon Lovestone, Kieran C. Murphy, Andrew Simmons, Declan G M Murphy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background: Down syndrome (DS), or trisomy 21, is one of the most common autosomal mutations. People with DS have intellectual disability (ID) and are at significantly increased risk of developing Alzheimer's disease (AD). The biological associates of both ID and AD in DS are poorly understood, but glutamate has been proposed to play a key role. In non-DS populations, glutamate is essential to learning and memory and glutamate-mediated excitotoxicity has been implicated in AD. However, the concentration of hippocampal glutamate in DS individuals with and without dementia has not previously been directly investigated. Proton magnetic resonance spectroscopy (<sup>1</sup>H MRS) can be used to measure in vivo the concentrations of glutamate-glutamine (Glx). The objective of the current study was to examine the hippocampal Glx concentration in non-demented DS (DS-) and demented DS (DS+) individuals. Methods: We examined 46 adults with DS (35 without dementia and 11 with dementia) and 39 healthy controls (HC) using <sup>1</sup>H MRS and measured their hippocampal Glx concentrations. Results: There was no significant difference in the hippocampal Glx concentration between DS+ and DS-, or between either of the DS groups and the healthy controls. Also, within DS, there was no significant correlation between hippocampal Glx concentration and measures of overall cognitive ability. Last, a sample size calculation based on the effect sizes from this study showed that it would have required 6,257 participants to provide 80% power to detect a significant difference between the groups which would indicate that there is a very low likelihood of a type 2 error accounting for the findings in this study. Conclusions: Individuals with DS do not have clinically detectable differences in hippocampal Glx concentration. Other pathophysiological processes likely account for ID and AD in people with DS.

Original languageEnglish
Article number42
JournalJournal Of Neurodevelopmental Disorders
Issue number1
Publication statusPublished - 27 Nov 2014


  • <sup>1</sup>H MRS
  • Alzheimer's disease
  • Dementia
  • Down syndrome
  • Glutamate-glutamine (Glx)
  • Hippocampus
  • Intellectual disability
  • Magnetic resonance spectroscopy


Dive into the research topics of 'Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: A preliminary study using in vivo proton magnetic resonance spectroscopy (<sup>1</sup>H MRS)'. Together they form a unique fingerprint.

Cite this